Tonix Pharma (TNXP) Misses Q4 EPS by 586c
Tweet
Share
E-mailGet Alerts TNXP Hot Sheet
Join SI Premium – FREE
Tonix Pharma (NASDAQ: TNXP) reported Q4 EPS of ($9.77), $5.86 worse than the analyst estimate of ($3.91). Revenue for the quarter came in at $2.58 million versus the consensus estimate of $3.2 million.
For earnings history and earnings-related data on Tonix Pharma (TNXP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades NAVER Corp. (035420:KS) (NHNCF) to Neutral
- Worthington Industries (WOR) Tops Q1 EPS by 7c
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
